We use first and third-party cookies to offer our services and collect statistical data. If you continue browsing this website you accept their use. More information Accept
PRODUCTS / PRODUCT PORTFOLIO
OTHER THERAPEUTIC AREAS

PRODUCT PORTFOLIO

Lesvi's product portfolio comprises CNS pharmaceuticals and nutraceuticals, unique dosage forms and products in other therapeutic areas such as antiemetic, anti-infective, cardiovascular, pain and respiratory diseases.
Product Indication Dosage form Strength
Fluconazol Antifungal Powder for oral suspension 200 mg/5ml and 50 mg/5ml
Hypromellose - Artificial tears Dry eye Eye drops, solution 0.5 ml (unit dose)
Imidapril * Hypertension Tablets 5, 10 and 20 mg
Ketorolac Analgesic Film-coated tablets 10 mg
Levetiracetam Epilepsy Film-coated tablets 250, 500, 750 and 1000 mg
Levetiracetam Epilepsy Granules for oral solution 250, 500, 750, 1000 and 1500 mg
Levetiracetam Epilepsy Oral solution 100 mg/ml
Levomethadone ** Pain, opiod maintenance therapy Oral solution 5 mg/ml
Levomethadone ** Pain, opiod maintenance therapy Oral drops, solution 5 mg/ml
Lisinopril Hypertension Tablets 5 and 20 mg
Lisinopril + HCTZ Hypertension Tablets 20/12.5 mg
Loratadine Allergy Film-coated tablets 10 mg
Memantine hydrochloride Alzheimer's disease Film-coated tablets 5, 10, 15 and 20 mg
Memantine hydrochloride Alzheimer's disease Oral solution 10 mg/ml
Methocarbamol Muscle spasms, pain Film-coated tablets 500, 750 and 1500 mg
Montelukast Asthma, allergy Chewable tablets 4 and 5 mg
Montelukast Asthma, allergy Film-coated tablets 10 mg
Noxiall® Useful to contrast chronic and neuropathic pain Jan 2017
Olanzapine Psychosis, schizophrenia Film-coated tablets 2.5, 5, 7.5, 10, 15 and 20 mg
Olanzapine Psychosis, schizophrenia Orodispersable tablets 5, 10, 15 and 20 mg
FDF PRODUCT PORTFOLIO

[*] Differentiated product
[**] Opioid

Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.


© Neuraxpharm / LESVI. All rights reserved.